Core Insights - The company Tongyuan Kang Pharmaceutical-B (02410.HK) announced early clinical research results for three drugs in the cyclin-dependent kinase (CDK) inhibitor field, specifically TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] Group 1: Clinical Research - The early clinical research results were presented in poster format at the European Society for Medical Oncology (ESMO) annual meeting [1] - The ESMO 2025 annual meeting took place from October 17-21, 2025, in Berlin, Germany [1] - ESMO is recognized as one of the most influential academic events in the oncology field, attracting top experts and scholars [1]

本公告乃由浙江同源康醫藥股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資 料。 本公司董事（「董事」）會（「董事會」）欣然宣佈重點佈局的細胞周期蛋白依賴性激 酶（「CDK」）抑制劑(CDKi)領域的三款藥物TYK-00540 (CDK2/4i)、TY-2699a (CDK7i)和TY-302 (CDK4/6i)的早期臨床研究結果以壁報形式在歐洲腫瘤內科學 會（「ESMO」）年會上展示。 ESMO 2025年會於當地時間2025年10月17-21日在德國柏林召開。作為全球腫瘤 學領域最具影響力的學術盛會之一，ESMO年會吸引了眾多學界頂尖專家學者， 提供了共同探討臨床難題、分享前沿進展的舞台。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 自願性公 ...

Summary of BeiGene Conference Call Company Overview - **Company**: BeiGene - **Industry**: Biotechnology and Pharmaceuticals Key Points and Arguments 1. **Global Commercialization Strategy**: BeiGene adopts a global commercialization strategy, leveraging Chinese patient resources and efficient clinical execution to reduce costs and accelerate global clinical trials, collaborating with international pharmaceutical companies like Novartis and Amgen [2][3] 2. **Core Product - Zanubrutinib**: Zanubrutinib has been approved in over 70 countries globally, becoming the leading BTK inhibitor for new patients in the U.S., surpassing the first-generation BTK inhibitor ibrutinib, significantly driving revenue growth for the company [2][5] 3. **Expansion into Solid Tumors**: BeiGene has made significant progress in the solid tumor field, with upcoming data releases for ADC, ProTech, and CDK, marking the company's transition from a focus on hematological malignancies to a broader oncology treatment approach [2][5] 4. **Clinical Trial Efficiency**: The company utilizes the cost and efficiency advantages of clinical trials in China, with 25% of global clinical patients from China and over 40% from Europe and North America, supporting simultaneous domestic and international product registrations [2][7] 5. **Upcoming Milestones**: Key milestones in the coming years include data readouts for ADC, ProTech, and CDK, as well as the submission of a BCL-2 inhibitor for U.S. market approval, which is expected to enhance the cure rate for frontline lymphoma patients [2][8] 6. **Unique Position in Chinese Innovation Drug Industry**: BeiGene is the only independent innovative drug company with global R&D and commercialization capabilities, making it a rare entity in the A-share and Hong Kong markets [3] 7. **Comprehensive Treatment Landscape**: In hematological malignancies, BeiGene has established a complete treatment portfolio including BTK, CDK, and BCL-2 inhibitors, with zanubrutinib expected to capture over 50% of the U.S. market share for CLL [4][12] 8. **BCL-2 Inhibitor Development**: The company is developing a new generation BCL-2 inhibitor, which is expected to achieve significant sales, potentially reaching $3 to $5 billion, and is currently undergoing global Phase III clinical trials [14][22] 9. **CDK Inhibitor Market**: BeiGene's CDK4/6 inhibitors are crucial in breast cancer treatment, with the global market exceeding $13 billion and projected to reach $16 to $18 billion [17][21] 10. **Broad Oncology Pipeline**: The company is actively developing treatments for various solid tumors, including lung and gastrointestinal cancers, with multiple products in clinical stages [20] Other Important but Overlooked Content 1. **Zanubrutinib's Competitive Edge**: Zanubrutinib's success is attributed to its superior product profile, showing better progression-free survival (PFS) and safety compared to ibrutinib, and being included in treatment guidelines [11][12] 2. **Impact of IRA Legislation**: The IRA legislation may have long-term effects on drug pricing, but currently, zanubrutinib has not faced price pressure, and its annual price has increased [13] 3. **Market Positioning**: BeiGene's international management team and shareholder structure, including significant overseas funds, support its global operations and strategic positioning [6][22] This summary encapsulates the critical insights from the conference call, highlighting BeiGene's strategic initiatives, product developments, and market positioning within the biotechnology industry.

Core Viewpoint - The company announced that three of its self-developed clinical products, TY-302, TY-2699a, and TY-0540, have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) conference, with detailed data to be published in the official ESMO journal, "Annals of Oncology" [1][2]. Group 1: Product Details - TY-302 is a potent, selective oral CDK4/6 inhibitor developed for treating advanced solid tumors such as breast and prostate cancer. It targets CDK4/6 to inhibit the phosphorylation of Rb, preventing cancer cell proliferation. Preclinical studies indicate lower gastrointestinal side effects and more controllable hematological toxicity compared to the leading CDK4/6 inhibitor, palbociclib. Phase I clinical data show significant efficacy and good safety when combined with tamoxifen for HR+/HER2- advanced breast cancer patients [1]. - TY-2699a is a selective CDK7 inhibitor aimed at treating advanced/metastatic solid tumors. Preclinical studies confirm its ability to precisely inhibit cancer cell growth at doses that do not affect normal cells. Initial clinical data demonstrate excellent safety and preliminary efficacy at similar dose levels. The data presented is from a Phase I multicenter monotherapy dose-escalation trial, with ongoing expansion trials for triple-negative breast cancer (TNBC) [2]. - TY-0540 is a selective CDK2 inhibitor intended for treating breast cancer, ovarian cancer, and other solid tumors. It shows strong inhibitory effects on key targets such as CDK2/CycA2 and CDK2/CycE1, while also exhibiting activity against related targets CDK4/CycD1 and CDK6/CycD3. Both preclinical and clinical studies indicate significant inhibitory effects and good safety profiles in various solid tumors, including models resistant to palbociclib. The data presented is from a Phase I multicenter open-label clinical trial, with ongoing Phase Ib/II studies [2].